Table 4.
Univariable and multivariable analysis of MCT1, MCT4, and MTCO1 expression and prognosis in 568 patients with gastric adenocarcinoma.
| MCT1 | MCT4 | MTCO1 | ||||
|---|---|---|---|---|---|---|
| Number of Patients | High MCT1 HR (95% CI) |
Number of Patients | High MCT4 HR (95% CI) |
Number of Patients | High MTCO1 HR (95% CI) |
|
| 5-year survival | ||||||
| All patients (Crude) |
560 | 1.06 (0.86–1.30) | 558 | 1.03 (0.84–1.26) | 562 | 1.08 (0.88–1.32) |
| All patients (Adjusted) a | 560 | 1.03 (0.84–1.26) | 558 | 1.07 (0.86–1.33) | 562 | 1.10 (0.90–1.35) |
| Subgroup analysis | ||||||
| Intestinal type (Crude) | 285 | 1.13 (0.85–1.50) | 283 | 1.14 (0.86–1.52) | 285 | 0.91 (0.69–1.21) |
| Intestinal type (Adjusted) b |
285 | 0.97 (0.72–1.30) | 283 | 1.17 (0.87–1.58) | 285 | 0.94 (0.71–1.25) |
| Diffuse type (Crude) | 257 | 1.04 (0.77–1.41) | 256 | 0.92 (0.67–1.26) | 258 | 1.28 (0.95–1.74) |
| Diffuse type (Adjusted) c |
257 | 1.09 (0.80–1.47) | 256 | 0.93 (0.67–1.30) | 258 | 1.30 (0.96–1.76) |
| Overall survival | ||||||
| All patients (Crude) | 560 | 1.11 (0.92–1.33) | 558 | 1.09 (0.91–1.31) | 562 | 1.08 (0.90–1.29) |
| All patients (Adjusted) a |
560 | 1.07 (0.89–1.28) | 558 | 1.08 (0.89–1.31) | 562 | 1.12 (0.93–1.35) |
| Subgroup analysis | ||||||
| Intestinal type (Crude) | 285 | 1.24 (0.96–1.59) | 283 | 1.12 (0.87–1.44) | 285 | 0.89 (0.69–1.15) |
| Intestinal type (Adjusted) b |
285 | 1.07 (0.82–1.39) | 283 | 1.14 (0.87–1.48) | 285 | 0.96 (0.75–1.24) |
| Diffuse type (Crude) | 257 | 1.04 (0.79–1.36) | 256 | 1.00 (0.75–1.34) | 258 | 1.26 (0.96–1.66) |
| Diffuse type (Adjusted) c |
257 | 1.10 (0.83–1.46) | 256 | 0.97 (0.72–1.31) | 258 | 1.27 (0.96–1.67) |
MCT1, MCT4 and MTCO1: Low expression HR (95% CI) 1.00 (Reference); a Adjusted for year of diagnosis, age, sex, tumor stage, Lauren classification, perioperative chemotherapy, and radical resection; b Adjusted for year of diagnosis, age, sex, tumor stage, tumor grade, perioperative chemotherapy, and radical resection; c Adjusted for year of diagnosis, age, sex, tumor stage, perioperative chemotherapy, and radical resection.